In the efficacy-evaluable population for ROZLYTREK, 41% had NTRK1 gene fusions, 2% had NTRK2 gene fusions, and 57% had NTRK3 gene fusions 1
There is no FDA-approved companion diagnostic for ROZLYTREK. 1
- NTRK gene fusions have been found in >25 tumor types, including 2,5,6
ETV6=ETS variant 6; FDA=US Food and Drug Administration; FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; MASC=mammary analogue secretory carcinoma; NGS=next-generation sequencing; NTRK=neurotrophic receptor tyrosine kinase; RT-PCR=reverse transcription polymerase chain reaction.
Available NGS platforms for TRK testing include:
- The list provided below may include some tests that are not FDA approved. Contact the individual lab for more information regarding a specific test. This list is non-exhaustive and is not intended to be a recommendation or endorsement of a specific laboratory or test
List is current as of August 2019.
Efficacy Across Tumor Types in Patients With NTRK Fusion-Positive Solid Tumors
View systemic efficacy data in patients with NTRK fusion-positive solid tumors, including response rates by tumor type
CNS Efficacy in Patients With NTRK Fusion-Positive Solid Tumors
View intracranial efficacy results in patients with NTRK fusion-positive solid tumors